Clinical Characteristics and Outcomes in Patients With Atrial Fibrillation and Pathogenic TTN Variants
Zain M Virk,Majd A El-Harasis,Zachary T Yoneda,Katherine C Anderson,Lili Sun,Joseph A Quintana,Brittany S Murphy,James L Laws,Giovanni E Davogustto,Matthew J O'Neill,Bibin T Varghese,Diane M Crawford,Hollie L Williams,Mahsima Shabani,Cassady J Pelphrey,Dakota D Grauherr,Kelsey Tomasek,Yan Ru Su,Megan C Lancaster,Quinn S Wells,Jeffrey M Dendy,Pablo Saavedra,Juan C Estrada,Travis D Richardson,Sharon T Shen,Arvindh N Kanagasundram,Jay A Montgomery,Christopher R Ellis,George H Crossley,Harikrishna Tandri,Prince J Kannankeril,Steven A Lubitz,William G Stevenson,Fei Ye,Patrick T Ellinor,Lynne W Stevenson,Dan M Roden,M Benjamin Shoemaker
DOI: https://doi.org/10.1016/j.jacep.2024.07.029
Abstract:Background: TTN encodes a sarcomeric protein called titin. Pathogenic rare variants in TTN are the most common finding in patients with atrial fibrillation (AF) and positive genetic testing. Objectives: This study sought to define the characteristics and outcomes in patients with AF and pathogenic TTN variants compared with genotype-negative patients with AF. Methods: Patients who presented initially with AF were enrolled in an AF registry. Retrospectively they underwent research sequencing for cardiomyopathy and arrhythmia genes. TTN(+) AF cases were defined as participants with pathogenic or likely pathogenic (P/LP) rare variants located in exons with high cardiac expression. They were matched 1:2 with control subjects with no P/LP variants. Phenotyping used retrospective manual chart review. Results: Among 2794 participants; 57 (2.0%) TTN(+) AF cases were identified and matched with 114 control subjects. Low QRS complex voltage was present more often in TTN(+) AF cases (18% vs 5%; P < 0.01), with no difference in PR, QRS interval, or QTc. More TTN(+) AF cases had persistent AF at enrollment (44% vs 30%; P = 0.028) and had undergone multiple cardioversions (61% vs. 37%; P < 0.01). By end of follow-up (median 8.3 years; Q1, Q3: 4.5, 13.7 years), 11% of TTN(+) AF cases developed sustained ventricular tachycardia/ventricular fibrillation, 44% left ventricular (LV) systolic dysfunction (LV ejection fraction <50%), and 47% met a combined endpoint of sustained ventricular tachycardia/ventricular fibrillation or LV systolic dysfunction. Conclusions: TTN(+) AF patients undergo more cardioversions and have more persistent forms of AF. Approximately 50% develop LV systolic dysfunction and/or malignant ventricular arrhythmias. These results highlight the need for diagnostic evaluation and management in TTN(+) patients beyond the usual care for AF.